Preview Mode Links will not work in preview mode

 

Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients.  In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.

Popular Topics

  • Virtual and digital health
  • Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
  • Value-based healthcare 
  • Precision and stratified medicine
  • Integration of digital technology into existing workflow and procedures 
  • Next-generation immuno, cell, and gene therapies
  • Vaccines
  • Biomarkers, sequencing, and imaging
  • Rare diseases
  • MedTech and medical devices
  • Clinical trials
  • Addressing Social Determinants of Health
  • Treating chronic conditions like obesity and pain
  • Clinician and staff burnout

The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors. 

 

Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.

Empowered Patient Solutions

Dec 27, 2022

Dr. Mark Sumeray is the Chief Medical Officer of Amolyt Pharma, focusing on rare diseases that affect the endocrine system, the hormonal system that regulates essential body functions. Despite the surgeon's best efforts, the parathyroid glands may be damaged or removed when operating on the thyroid gland creating permanent hypoparathyroidism. As a result, the body does not produce sufficient levels of the parathyroid hormone, which regulates the level of calcium in the blood. Current treatment includes large doses of calcium tablets and vitamin D, which does not address disabling symptoms and long-term complications for the kidney, heart, and brain.

Mark explains, "If you have a deficiency of a hormone, in this case, the parathyroid hormone, then the most obvious thing to do is to replace the missing hormone by giving the hormone or something very similar to the hormone to the patient. So instead of the glands producing the hormone as they should do in the normal situation, in this case, we give something that acts like parathyroid hormone by injection."

"The company has a peptide, which is a type of chemical that is made up of building blocks of amino acids that looks very similar to parathyroid hormone, the missing hormone, but has some important differences to it. It's been specifically synthesized or created by chemists to mimic the action of the natural hormone, and it is given by injection every day to patients. And then, as I mentioned right at the beginning, it's currently in early-stage clinical trials."

@AmolytPharma #Hypoparathyroidism #RareEndocrine #TherapeuticPeptides #Endocrine #RareDisease #Acromegaly #Endocrinology

amolytpharma.com

Download the transcript here

Amolyt